Record-Breaking Price Movement
On 12 Dec 2025, Venus Remedies touched Rs.839, setting a fresh 52-week and all-time high benchmark. This milestone comes amid a day where the stock recorded a 1.71% gain, outperforming the Sensex’s 0.27% rise. Despite an intraday low of Rs.790.65, representing a 4.26% dip from the peak, the stock maintained its position above critical moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day marks. This sustained upward momentum highlights the stock’s strong technical foundation.
Long-Term Performance Outpaces Market Benchmarks
Venus Remedies’ price performance over various time horizons reveals a consistent pattern of market-beating returns. Over the past year, the stock has recorded a return of 148.14%, significantly surpassing the Sensex’s 4.62% during the same period. Year-to-date figures show an even more pronounced difference, with Venus Remedies at 166.52% against the Sensex’s 8.84%. Extending the view further, the company’s three-year return stands at 345.01%, compared to the Sensex’s 36.88%, while the five-year and ten-year returns are 490.27% and 584.00% respectively, dwarfing the Sensex’s 84.48% and 239.58% over those intervals.
Rising fast and still accelerating! This Small Cap from FMCG sector is riding pure momentum right now. Jump in before the rally reaches its peak!
- - Accelerating price action
- - Pure momentum play
- - Pre-peak entry opportunity
Financial Strength and Profitability Metrics
Venus Remedies’ financial results over recent quarters have demonstrated a robust upward trend. The company reported a net profit growth of 473.5% in the September 2025 quarter, reflecting very positive results. Over the latest six months, the profit after tax (PAT) reached Rs.29.73 crores, marking a growth of 528.54%. Profit before tax less other income (PBT less OI) for the quarter stood at Rs.24.78 crores, with a substantial growth rate of 2073.68%. These figures indicate a strong earnings momentum underpinning the stock’s price performance.
Return on Capital and Valuation Considerations
The company’s return on capital employed (ROCE) for the half-year period is recorded at 13.99%, the highest in its recent history, signalling efficient utilisation of capital resources. Return on equity (ROE) is at 10.5%, which, combined with a price-to-book value of 1.9, suggests an attractive valuation relative to its sector peers. The stock’s price-to-earnings-to-growth (PEG) ratio stands at 0.1, reflecting the relationship between its price, earnings growth, and valuation in a favourable light.
Market Capitalisation and Debt Profile
Venus Remedies holds a market capitalisation grade of 4, indicating a mid-sized company within its sector. The company’s average debt-to-equity ratio is zero, highlighting a debt-free balance sheet that supports financial stability and reduces leverage-related risks.
Recent Price Trends and Sector Comparison
While Venus Remedies recorded a 1.71% gain today, it underperformed its sector by 1.56%. The stock experienced a reversal after two consecutive days of gains, reflecting typical market fluctuations. However, its performance over the past week, month, and quarter remains strong, with returns of 12.71%, 56.24%, and 85.44% respectively, compared to the Sensex’s negative 0.78% weekly return and modest monthly and quarterly gains of 0.68% and 3.83%.
Curious about Venus Remedies from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Investor Composition and Market Presence
Despite its size and performance, domestic mutual funds currently hold no stake in Venus Remedies. This absence of mutual fund ownership may reflect a cautious stance or differing assessment of the company’s valuation or business model. Such a scenario is notable given the capacity of domestic funds to conduct detailed on-the-ground research.
Summary of Venus Remedies’ Journey to the All-Time High
Venus Remedies’ ascent to Rs.839 is the culmination of sustained earnings growth, strong capital efficiency, and consistent market outperformance. The company’s ability to maintain profitability growth over four consecutive quarters, alongside a debt-free balance sheet, has contributed to its rising valuation. Its long-term returns have outpaced major indices by a wide margin, reflecting a compelling track record within the Pharmaceuticals & Biotechnology sector.
While the stock experienced some volatility intraday, its position above key moving averages and robust financial metrics provide a solid foundation for its current valuation. The milestone of an all-time high price is a significant marker in the company’s market journey, reflecting both operational strength and investor confidence in its established business model.
Conclusion
Venus Remedies’ achievement of a new all-time high price at Rs.839 represents a noteworthy event in the Indian pharmaceuticals market. The company’s financial performance, valuation metrics, and market returns collectively illustrate a strong growth narrative. This milestone highlights the company’s evolution and its standing within the sector, supported by consistent profitability and capital management.
Only ₹14,999 - Get MojoOne + Stock of the Week for 2 Years PLUS 6 Months FREE Claim 83% OFF →
